Similarly, when comparing nateglinide and acarbose to target postprandial hyperglycaemia in new-onset, non-insulin requiring individuals with diabetes, improvement of post-meal flow-mediated dilatation was noted with an edge of acarbose over nateglinde [94] (as to the acarbose studies see further down). The gene discussed is INS; the disease is Hyperglycemia.